Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001837607-25-000050
Filing Date
2025-05-14
Accepted
2025-05-14 16:10:19
Documents
70
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q aeon-20250331x10q.htm   iXBRL 10-Q 1342871
2 EX-31.1 aeon-20250331xex31d1.htm EX-31.1 16129
3 EX-31.2 aeon-20250331xex31d2.htm EX-31.2 16047
4 EX-32.1 aeon-20250331xex32d1.htm EX-32.1 8727
5 EX-32.2 aeon-20250331xex32d2.htm EX-32.2 8840
  Complete submission text file 0001837607-25-000050.txt   7501835

Data Files

Seq Description Document Type Size
6 EX-101.SCH aeon-20250331.xsd EX-101.SCH 61130
7 EX-101.CAL aeon-20250331_cal.xml EX-101.CAL 40720
8 EX-101.DEF aeon-20250331_def.xml EX-101.DEF 269802
9 EX-101.LAB aeon-20250331_lab.xml EX-101.LAB 473983
10 EX-101.PRE aeon-20250331_pre.xml EX-101.PRE 395772
73 EXTRACTED XBRL INSTANCE DOCUMENT aeon-20250331x10q_htm.xml XML 1387172
Mailing Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614
Business Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614 (949) 354-6499
AEON Biopharma, Inc. (Filer) CIK: 0001837607 (see all company filings)

EIN.: 853940478 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40021 | Film No.: 25945550
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)